On July 19, 2021, US President Joe Biden’s administration released a proposed rule that would increase penalties for hospitals that do not comply with the Hospital Price Transparency Rule, effective January 1, 2022. According to McDermott’s Emily Jane Cook and Steven J. Schnelle, the proposed rule also provides certain potentially burdensome clarifications and requests comment on further rulemaking activity relating to the Hospital Price Transparency Rule.
CMS Proposes Heightened Penalties and Additional Requirements Under the Hospital Price Transparency Rule
By Emily J. Cook and Steven J. Schnelle on September 28, 2021
Posted In Employee Benefits, Health and Welfare Plans
Emily J. CookIn today’s complex and fast-changing healthcare regulatory environment, Emily Jane Cook helps healthcare organizations thrive. Innovative start-ups and established market leaders alike turn to Emily for broad-spectrum strategies to fuel new business initiatives and solve their most pressing compliance, transactional, reimbursement and litigation challenges. Emily is a practice area leader for the Healthcare Regulatory & Compliance practice. In addition to Emily’s role as a national authority on the 340B drug pricing program, Emily helps clients navigate the full suite of federal and state regulations that are essential to healthcare operations. She partners with a wide range of organizations, including non-traditional service providers and new market entrants to identify, protect and expand revenue opportunities, including via private-equity-backed ventures. Her comprehensive counsel encompasses evolving issues such as No Surprises Act (NSA) implementation, development of new provider types, Medicare provider-based and co-location rules, and trends in qui tam litigation and government investigations. She works closely with colleagues in McDermott’s transactional, litigation and private equity practices to deliver fully realized solutions for her clients. Read Emily Cook's full bio.
Steven J. SchnelleSteven Schnelle focuses his practice on regulatory and transactional matters involving health care providers and suppliers, pharmacies, pharmaceutical firms, device manufacturers, and market innovators. Read Steven Schnelle's full bio.
Related Posts
- Trump-Era Medicare Program Under Increased Scrutiny
- Fifth Circuit Brings Enforcement Back into the Mix: The Latest Court Moves with the CMS Vaccination Mandate
- CMS Will Finalize Heightened Penalties, Additional Requirements Under Hospital Price Transparency Rule
- 2024 Chart of Healthcare Regulations
- CMS Approves New York 1115 Medicaid Redesign Waiver
BLOG EDITORS
STAY CONNECTED
TOPICS
ARCHIVES
RECENT POSTS
- CMS Issues Guidance on Usage of AI in Making Coverage Determinations
- 2024 Chart of Healthcare Regulations
- Potential Election Year Shakeup: Regulatory Implications of the Congressional Review Act
- Lessons from Ryan S. v. UnitedHealth Group for the 2023 MHPAEA Proposed Rule
- Hospital Settles With OCR for $4.75 Million Over HIPAA Violations
